January 2017

Safety Related Changes

Erythrocin IV (erythromycin lactobionate) is contraindicated in the case of hypersensitivity to other antibiotics from the macrolide family; severely impaired hepatic function; concurrent treatment with HMG-CoA reductase inhibitors (e.g. lovastatin or simvastatin); congenital or acquired QT interval prolongation; clinically relevant cardiac arrhythmias (e.g. ventricular arrhythmias) or in severe congestive heart failure (NYHA IV); concomitant intake of medicinal products, which can lead to prolongation of the QT interval and under some circumstances to life-threatening ventricular arrhythmia (torsade de pointes) e.g. terfenadine, astemizole, cisapride, pimozide, domperidone, class IA and III antiarrhythmics (e.g. disopyramide), certain neuroleptics, tri- and tetracyclic antidepressants, arsenic trioxide, methadone, budipine, certain fluoroquinolones, imidazole anti-mycotics and anti-malarials (e.g. pentamidin i.v.); disturbances of the electrolyte balance (especially in the case of hypokalaemia and hypomagnesaemia) and rapid administration by direct intravenous injection (IV push).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629